In human T lymphocytes patch-clamp experiments have revealed the expression of two major subtypes of SK channels. In excitable cells these channel types play significant roles in shaping excitablility as well as firing patterns especially since their open probability is regulated by the intracellular second messenger Ca2+. In nonexcitable T cells, SK channels could hyperpolarize the membrane during the rise in [Ca2+]i elicited via T-cell receptor stimulation. This hyperpolarization in turn could contribute to enhanced Ca2+ entry by increasing the driving force for Ca2+ to enter the cell [see also Verheugen, this issue] via Icrac· This scenario plays an increasingly significant role in already activated T cells due to the up-regulated number of SK channels in activated human peripheral T lymphocytes. We have used whole-cell recording to determine the electrophysiological properties of current through SKAPA channels in Jurkat T cells and through SKctx channels in activated HPB T lymphocytes. The main similarities between the two channel types are their Ca2+ sensitivity and voltage dependence. The SK channel activity depends steeply on [Ca2+]i, suggesting that multiple Ca2+ must bind to the channel or an associated molecule in order to open the pore. The Ca2+ concentration at which half the channels are activated is Ì° 400-450 nM and the activity of both channel types is voltage-independent. The major difference between the two channel types is their pharmacology regarding peptide toxins like apamin, scyllatoxin, charybdotoxin, as well as other blockers like TEA+. SKcTX and SKapa channels show minor differences in Ba2+ sensitivity, induction time course, selectivity, and single-channel conductance. All these properties together should allow a better distinction between these two different types of SK channels in lymphocytes with the ultimate goal to identify the genes encoding these channels.

Journal Section:
Original Paper
Keywords:
Small calcium-activated potassium channels, SK channels, Electrophysiology, Apamin, Scyllatoxin, Charybdotoxin
This content is only available via PDF.
© 1997 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
1997
You do not currently have access to this content.